Left ventricular thrombus in Takotsubo syndrome and ST-elevation myocardial infarction Authors: Sandeep Jha, Moa Simonsson, Angela Poller, Linnea Molander, Sigurdur Thorleifsson, Carlo Pirazzi, Sara Bentzel, Petronella Torild, Erik A Andersson, Aaron Shekka Espinosa, Valentyna Sevastianova, Sabin Salahuddin, Rickard Zeijlon, Ahmed Elmahdy, Kristofer Skoglund, Elmir Omerovic, Björn Redfors Published: 2026 ABSTRACT AbstractBackgroundBoth Takotsubo syndrome (TS) and ST-elevation myocardial infarction (STEMI) are conditions characterised by the acute onset of left ventricular (LV) dysfunction. While LV thrombus is a known complication of LV dysfunction, its epidemiology in these two patient groups remains poorly understood.MethodsWe used data from the Stunning in Takotsubo versus Acute Myocardial Infarction (STAMI) study, which prospectively enrolled patients with TS and STEMI at Sahlgrenska University Hospital. Serial echocardiography was performed on admission and on days 1, 2, 3, 7, 14 and 30. Predictors of LV thrombus were identified using Cox regression analyses.Results314 patients were included; 68 with TS, 148 with anterior STEMI and 98 with non-anterior STEMI. Mean LV ejection fraction (LVEF) at admission was 39% (95% CI 35.8 to 42.2) in TS, 46.7% (95% CI 43.3 to 50.1) in anterior STEMI and 52.8% (95% CI 48.9 to 56.7) in non-anterior STEMI. LV thrombus occurred in 20 of 246 (8.1%) STEMI patients but in none of the TS patients. All but one LV thrombus was found in anterior STEMI. All LV thrombi in anterior STEMI were detected within 7 days, while the single non-anterior LV thrombus was found on day 30. All patients with LV thrombi received anticoagulation. Predictors of LV thrombus included lower LVEF and higher troponin levels.ConclusionsDespite more severe LV dysfunction in TS compared with STEMI, LV thrombus was exclusively found in STEMI patients. Almost all LV thrombi were found in anterior STEMI within the first week and showed a high-resolution rate at 30 days. Our findings highlight pathophysiological differences between these two conditions, warranting further investigation and implications for differing surveillance needs after TS and STEMI. WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS Left ventricular thrombus occurred predominantly in anterior STEMI and largely resolved by 30 days, despite more extensive left ventricular dysfunction in TS. Left ventricular thrombus occurred predominantly in anterior STEMI and largely resolved by 30 days, despite more extensive left ventricular dysfunction in TS. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings emphasise the need to define optimal imaging strategies for early left ventricular thrombus detection. They also support more individualised anticoagulation approaches and provide a rationale for prospective studies to refine contemporary management. These findings emphasise the need to define optimal imaging strategies for early left ventricular thrombus detection. They also support more individualised anticoagulation approaches and provide a rationale for prospective studies to refine contemporary management. Introduction Left ventricular (LV) thrombus is a recognised complication of acute myocardial dysfunction, posing significant morbidity due to its potential to cause stroke or systemic embolisation.13 In ST-elevation myocardial infarction (STEMI), the extent of myocardial wall motion abnormalities is associated with the risk of LV thrombus formation.4 5 Takotsubo syndrome (TS) is a transient and reversible condition characterised by widespread LV dysfunction triggered by emotional or physical stress. Unlike STEMI, TS occurs in the absence of coronary artery obstruction and predominantly affects postmenopausal women.6 In both TS and STEMI, these LV wall abnormalities can result in blood stasis, endothelial dysfunction and hypercoagulability, fulfilling all three components of Virchow’s triad and predisposing patients to thrombus formation.7 However, the incidence, timing, clinical relevance and outcomes of thrombus formation in these conditions remain poorly defined. Most previous studies on LV thrombus incidence have been retrospective and limited by small sample sizes. In addition, they have lacked standardised echocardiographic surveillance and detailed data on the timing of thrombus formation, associated risk factors and concomitant medical therapy.5 8 Consequently, significant gaps persist in understanding risk factors, timing of thrombus formation and thrombus resolution after STEMI and TS. This study aims to fill these gaps by comprehensively assessing LV thrombus incidence and resolution in prospectively enrolled patients with TS or STEMI through repeated echocardiographic assessments over the first 30 days. Methods Study design Stunning in Takotsubo versus Acute Myocardial Infarction (STAMI, NCT04448639) is an ongoing prospective observational study. Patients with TS or STEMI without preexisting cardiac dysfunction undergo echocardiography, electrocardiography and laboratory assessment within 4 hours of admission and on days 1, 2, 3, 7, 14 and 30. TS and STEMI were defined according to the European Society of Cardiology diagnostic criteria.9 Patients with STEMI were required to undergo primary PCI within 6 hours of symptom onset. Patient and public involvement Patients and the public were not involved in the design, reporting or dissemination of this study. Patients participated in the study and went through the study protocol after they gave written informed consent during their index hospitalisation. Definitions and outcomes Examinations were performed by experienced sonographers in accordance with a study-specific manual of operations, and standard apical views (four-chamber, two-chamber and three-chamber) were acquired with a focus on endocardial border delineation and regional wall motion assessment.10 The primary outcome was the incidence of LV thrombus formation within 30 days. A thrombus was defined as an echogenic mass distinct from the endocardium, visualised in multiple views and located in a region of wall motion abnormality. Thrombi were classified as mural when adherent to the ventricular wall with a broad-based attachment and without independent motion, and as mobile when protruding into the ventricular cavity with independent motion (figure 1).11 All suspected thrombi were reviewed by experienced cardiologists with expertise in echocardiographic interpretation. In cases of diagnostic uncertainty, additional imaging, including contrast echocardiography or cardiac MRI, was performed when clinically indicated. Left ventricular (LV) thrombi (arrows) visualised with transthoracic echocardiography (TTE), with or without contrast. Image quality was assessed according to routine clinical standards, and studies with insufficient visualisation of the LV apex were re-evaluated or supplemented with contrast imaging when deemed necessary. The secondary outcomes were thrombus resolution rate and functional recovery in anterior STEMI patients with LV thrombus compared with those without LV thrombus. Additional endpoints included predictors of LV thrombus formation, including LV ejection fraction (LVEF), global longitudinal strain (GLS), serum biomarkers and proportion of akinesia (PrA), which was defined as the proportion of the LV endocardial length that was akinetic, measured in the apical 2-chamber and 4-chamber views at end-diastole. Akinesia resolution was defined as the change in PrA from baseline (day 0) to day 3, and total akinesia resolution as the change in PrA from baseline to day 30. Clinical outcomes were systematically assessed during hospitalisation, at 30 days and at 6 months. Prespecified outcomes within the first 3 days included cardiogenic shock, ventricular fibrillation, sustained ventricular tachycardia and advanced atrioventricular block (grade II–III). Outcomes within 30 days comprised all-cause death, recurrent myocardial infarction, hospitalisation for heart failure, stroke or transient ischaemic attack (TIA) and systemic thromboembolism (excluding stroke/TIA). The same outcomes were evaluated again at 6 months. Statistical analyses Continuous data are reported as mean±SD for normally distributed variables and median (quartile 1 (Q1), quartile 3 (Q3)) for skewed variables. Categorical data are reported as frequency (percentage). For the modelling of akinesia recovery, time was included as a fixed categorical variable, and patient-specific trajectories were modelled using ‘random’ intercepts. Anterior STEMI with thrombi and without thrombi were fitted separately, allowing both group-specific reference trajectories and differences in patient and within-patient variation. Mixed-effects linear regression was used to model temporal variation in echocardiographic and laboratory parameters, with time as a fixed categorical effect and random intercepts per patient ID. The model was used uniformly for variables with a normal distribution (LVEF, GLS, tricuspid annular plane systolic excursion (TAPSE)) and for those conforming to normality after logarithmic transformation, that is, troponin-I (TnI), troponin-T (TnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), TnI/TnT-ratio, NT-proBNP/TnI-ratio, NT-proBNP/TnT-ratio. Cox proportional hazards regression models were used to evaluate predictors of LV thrombus formation. Prespecified predictors included baseline LVEF, GLS, TAPSE, TnI, NT-proBNP, hypertension, chronic obstructive pulmonary disease (COPD) and hyperlipidaemia. Each predictor was evaluated in a separate model adjusted for age and sex, with age and sex mutually adjusted for one another. The models included echocardiographic and biomarker parameters as time-varying (LVEF, GLS, TAPSE, TnI, TnT and NT-proBNP). At the same time, all other variables were incorporated as standard, time-fixed predictors (COPD, diabetes, hypertension, hyperlipidaemia, peak TnI, peak NT-proBNP, age, sex). Before fitting the Cox models, missing values in the echocardiographic and biomarker data were imputed using two-level predictive mean matching (2l.pmm) via the mice R-package. All statistical analyses were performed with R V.4.4.1. Results Study population From December 2019 to October 2024, 314 patients were included: 68 with TS, 148 with anterior STEMI and 98 with non-anterior STEMI. TS patients were predominantly female (91.2%) and slightly older (67.6±13.2 years), while the STEMI groups had lower proportions of females (anterior 27.7%, non-anterior 22.4%) and similar mean ages (anterior 65.7±11.5 years, non-anterior 66.3±10.9 years). Median BMI was lowest in the TS group. Comorbidities such as diabetes, hypertension and hyperlipidaemia were comparable across all groups. The model-estimated mean LVEF at admission was lower in TS (39%) than in anterior STEMI (46.7%) and non-anterior STEMI (52.8%). However, recovery was faster and more pronounced in TS, with a mean LVEF of 60.4% at day 30, compared with 53.8% in anterior STEMI and 55.3% in non-anterior STEMI (table 1). Table 1Demographics and patient characteristicsBaseline characteristicAnterior STEMI n=148Non-anterior STEMI n=98Takotsubo n=68Sex (women)41/148 (27.7%)22/98 (22.4%)62/68 (91.2%)Age (years)65.7±11.566.3±10.967.6±13.2BMI (kg/m²)26.4 (24.0–29.2)26.6 (24.3–29.4)25.0 (22.3–29.2)Diabetes18/148 (12.2%)11/98 (11.2%)6/68 (8.8%)Hypertension54/148 (36.5%)44/98 (44.9%)31/68 (45.6%)Hyperlipidaemia23/147 (15.6%)15/98 (15.3%)13/68 (19.1%)Atrial fibrillation Chronic0/148 (0.0%)1/98 (1.0%)1/68 (1.5%) Paroxysmal2/148 (1.4%)2/98 (2.0%)6/68 (8.8%) Persistent0/148 (0.0%)0/98 (0.0%)1/68 (1.5%)Chronic obstructive pulmonary disease7/148 (4.7%)5/98 (5.1%)6/68 (8.8%)Peripheral vascular disease4/148 (2.7%)2/98 (2.0%)5/68 (7.4%) Chronic renal disease6/148 (4.1%)2/98 (2.0%)2/67 (3.0%)Prior stroke4/148 (2.7%)5/98 (5.1%)4/68 (5.9%)Prior stroke type Ischaemic3/4 (75.0%)5/5 (100.0%)4/4 (100.0%)Smoking status Current smoker (within 30 days)40/148 (27.0%)18/98 (18.4%)8/68 (11.8%) Former smoker (>30 days ago)33/148 (22.3%)25/98 (25.5%)21/68 (30.9%) Never75/148 (50.7%)55/98 (56.1%)39/68 (57.4%)Takotsubo trigger Somatic––23/68 (33.8%) Emotional––28/68 (41.2%) None––17/68 (25.0%)Chest pain140/148 (94.6%)94/98 (95.9%)37/68 (54.4%)Dyspnoea51/148 (34.5%)26/98 (26.5%)37/68 (54.4%)Heart rhythm admission Sinus142/148 (95.9%)93/96 (96.9%)62/65 (95.4%) Atrial fibrillation or flutter5/148 (3.4%)3/96 (3.1%)1/65 (1.5%) Pacemaker1/148 (0.7%)0/96 (0.0%)2/65 (3.1%)Heart rate at admission (BPM)79.1±18.568.0±17.295.0±23.2SBP at admission (mm Hg)138.1±24.1135.2±25.4131.0±27.1DBP at admission (mm Hg)84.5±16.081.1±16.184.1±17.2Killip class admission I124/148 (83.8%)96/98 (98.0%)46/67 (68.7%) II13/148 (8.8%)0/98 (0.0%)12/67 (17.9%) III8/148 (5.4%)1/98 (1.0%)6/67 (9.0%) IV3/148 (2.0%)1/98 (1.0%)3/67 (4.5%)Oxygen at admission23/148 (15.5%)7/98 (7.1%)21/67 (31.3%)LVEF (%) at serial timepoints 046.7 (43.3, 50.1)52.8 (48.9, 56.7)39 (35.8, 42.2) 146.8 (43.4, 50.1)53.6 (49.7, 57.4)39.1 (36.1, 42.2) 248.3 (44.9, 51.7)53.1 (49.2, 57)46 (43.1, 48.9) 349.5 (46.1, 52.9)55.2 (51.2, 59.3)48.7 (45.7, 51.8) 750.9 (47.5, 54.4)54 (50, 57.9)52.3 (49.4, 55.3) 1452.3 (48.8, 55.8)54.9 (51, 58.8)58.3 (55.2, 61.4) 3053.8 (50.3, 57.3)55.3 (51.4, 59.2)60.4 (57.3, 63.5)Data are shown as n/N (%), mean ± SD or median (interquartile range). LVEF day is shown as predicted mean (95% CI). BMI, body mass index; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; TS, takotsubo syndrome. Demographics and patient characteristics Data are shown as n/N (%), mean ± SD or median (interquartile range). LVEF day is shown as predicted mean (95% CI). BMI, body mass index; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; TS, takotsubo syndrome. Primary outcome LV thrombus was identified in 20 of 246 patients with STEMI (8.1%), with a clear predominance in anterior STEMI (n=19), while only one event occurred in non-anterior STEMI. No LV thrombus was observed in patients with TS. All LV thrombus in anterior STEMI were detected within the first 7 days of admission, whereas the lone thrombus in the non-anterior STEMI group was detected on day 30. Of the 20 thrombi, 9 (45.0%) were classified as mural and 11 (55.0%) as mobile. By day 30, the resolution of the thrombus was observed in 16 out of the 20 cases. Table 2 provides detailed characteristics of the STEMI thrombus cases, including patient demographics, infarct location, thrombus morphology and timing of detection. Table 2Description of left ventricular thrombus and anticoagulation per patientPatient numberSexSTEMI localisationLVEF admissionLVEF day 30Thrombus detection dayThrombus MuralThrombus mobilityThrombus resolution within 30 daysThrombo-embolism within 30 daysAnticoagulation1WAnterior45607NoYesYesNoWarfarin2MAnterior50307NoYesNoNoHeparin + Warfarin3MAnterior40503YesNoYesNoLMWH + Warfarin4MAnterior20NA1NoYesYesNoHeparin + Warfarin → DOAC (patient preference)5MAnterior35457NoYesNANoHeparin + Warfarin6MAnterior40600NoYesYesNoLMWH + Warfarin7MAnterior45403YesNoYesNoLMWH + Warfarin8MAnterior25303YesNoYesNoDOAC → Warfarin9MAnterior40352YesNoYesNoLMWH + Warfarin10MAnterior50557NoYesYesNoHeparin + Warfarin11MAnterior40503YesNoYesNoLMWH + Warfarin12MAnterior45407YesNoYesNoLMWH + Warfarin13WAnterior35NA3YesNoYesNoLMWH + DOAC14MAnterior30453NoYesYesNoLMWH + Warfarin15MAnterior45355NoYesYesNoLMWH + Warfarin16MAnterior40NA2NoYesYesNoLMWH + DOAC17MAnterior25407NoYesYesNoLMWH + DOAC18MAnterior45552YesNoNoYesHeparin + Warfarin19MAnterior20450YesNoYesNoDOAC20WNon-anterior453530NoYesNoNoHeparin + Warfarin→, switched to; DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; LVEF, left ventricular ejection fraction; M, man; NA, not available; STEMI, ST-elevation myocardial infarction; W, woman. Description of left ventricular thrombus and anticoagulation per patient →, switched to; DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; LVEF, left ventricular ejection fraction; M, man; NA, not available; STEMI, ST-elevation myocardial infarction; W, woman. Secondary outcomes Given that LV thrombus was predominantly observed in anterior STEMI, a detailed analysis of this subgroup was performed. Tables3 4 comprehensively compare anterior STEMI patients with and without LV thrombus, highlighting significant differences in clinical and echocardiographic parameters. Table 2 details the resolution patterns, showing that 8 of the nine mural thrombi (88.9%) and 8 of the 11 mobile thrombi (72.7%) resolved by day 30 (80%). Functional recovery, as measured through improvements in GLS, was less pronounced in thrombus-positive patients compared with thrombus-negative patients. Table 3Patient characteristics for anterior STEMI patients with or without left ventricular thrombusBaseline characteristicLV thrombus n=19Without LV thrombus n=129Sex (women)2/19 (10.5%)39/129 (30.2%)Age (years)70.9±12.665.0±11.1BMI (kg/m²)25.6 (23.6–29.5)26.4 (24.1–29.1)Diabetes1/19 (5.3%)17/129 (13.2%)Hypertension9/19 (47.4%)45/129 (34.9%)Hyperlipidaemia5/19 (26.3%)18/128 (14.1%)Atrial fibrillation No19/19 (100.0%)127/129 (98.4%) Paroxysmal0/19 (0.0%)2/129 (1.6%)Chronic obstructive pulmonary disease2/19 (10.5%)5/129 (3.9%)Peripheral vascular disease0/19 (0.0%)4/129 (3.1%)Chronic renal disease1/19 (5.3%)5/129 (3.9%)Prior stroke0/19 (0.0%)4/129 (3.1%) Ischaemic0/0 (NA%)3/4 (75.0%)Smoking status Current smoker (within 30 days)4/19 (21.1%)36/129 (27.9%) Former smoker (>30 days ago)7/19 (36.8%)26/129 (20.2%) Never8/19 (42.1%)67/129 (51.9%) Chest pain18/19 (94.7%)122/129 (94.6%) Dyspnoea4/19 (21.1%)47/129 (36.4%)Heart rhythm admission Sinus17/18 (94.4%)124/128 (96.9%) Atrial fibrillation or flutter0/18 (0.0%)4/128 (3.1%)Heart rate at admission (BPM)78.5±19.579.2±18.4SBP at admission (mm Hg)134.8±17.4138.4±25.0DBP at admission (mm Hg)85.9±10.784.4±16.7Killip class admission I17/18 (94.4%)106/128 (82.8%) II0/18 (0.0%)13/128 (10.2%) III1/18 (5.6%)6/128 (4.7%) IV0/18 (0.0%)3/128 (2.3%)Oxygen at admission1/18 (5.6%)21/128 (16.4%)Data are shown as n/N (%), mean ± SD, or median (interquartile range).BMI, body mass index; DBP, diastolic blood pressure; LV, left ventricular; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction. Patient characteristics for anterior STEMI patients with or without left ventricular thrombus Data are shown as n/N (%), mean ± SD, or median (interquartile range). BMI, body mass index; DBP, diastolic blood pressure; LV, left ventricular; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction. Table 4Drugs at baseline and discharge in patients with anterior STEMI stratified by left ventricular thrombus statusBaseline drugsWith LV thrombusWithout LV thrombusn=19n=129Anti-diabetic drugs type of anti-diabetic drug1/19 (5.2%)17/129 (13.2%) Metformin1/1 (100.0%)10/17 (58.8%) SGLT2i0/1 (0.0%)3/17 (17.6%) Other antidiabetics0/1 (0.0%)4/17 (23.5%)Anti-androgen drugs3/19 (15.8%)5/129 (3.9%)Corticosteroids3/19 (15.8%)10/129 (7.8%)NSAID2/19 (10.5%)1/129 (0.8%)Paracetamol3/19 (15.8%)8/129 (6.2%)ASA1/19 (5.3%)8/129 (6.2%)P2Y12i1/19 (5.3%)4/129 (3.1%)P2Y12i type Clopidogrel1/1 (100.0%)3/4 (75.0%) Ticagrelor0/1 (0.0%)1/4 (25.0%)Oral anticoagulants2/19 (10.5%)3/129 (2.3%)Oral anticoagulants type Apixaban0/2 (0.0%)2/3 (66.7%) Rivaroxaban1/2 (50.0%)1/3 (33.3%) Warfarin1/2 (50.0%)0/3 (0.0%) Long-acting nitrates1/19 (5.3%)2/129 (1.6%) Beta blocker3/19 (15.8%)15/129 (11.6%) ACEi3/19 (15.8%)6/129 (4.7%) ARB2/19 (10.5%)22/129 (17.1%) MRA0/19 (0.0%)3/129 (2.3%) Calcium channel blocker3/19 (15.8%)20/129 (15.5%) Alpha blocker0/19 (0.0%)2/129 (1.6%) Loop diuretic0/19 (0.0%)2/129 (1.6%) Thiazide diuretic0/19 (0.0%)4/128 (3.1%) Statin3/19 (15.8%)17/129 (13.2%) Ezetrol1/19 (5.3%)3/129 (2.3%)Discharge drugsWith LV thrombusWithout LV thrombusn=19n=126*ASA taken throughout 30 days12/19 (63.2%)111/126 (88.1%)P2Y12i taken throughout 30 days19/19 (100.0%)125/126 (99.2%)Beta blocker administered within 30 days19/19 (100.0%)110/126 (87.3%)ACEi or ARB administered within 30 days19/19 (100.0%)120/126 (95.2%)Neprilysin inhibitor administered within 30 days1/19 (5.3%)5/126 (4.0%)Statin administered within 30 days17/19 (89.5%)121/126 (96.0%)Oral anticoagulants administered within 30 days18/19 (94.7%)14/126 (11.1%)Long acting nitrates administered within 30 days0/19 (0.0%)1/126 (0.8%)Data are shown as n/N (%).*3 deaths before discharge.ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; MRA, mineralocorticoid receptor antagonist; NSAID, non-steroidal anti-inflammatory drugs; P2Y12i, P2Y12 inhibitor; SGLT2i, SGLT2 inhibitor. Drugs at baseline and discharge in patients with anterior STEMI stratified by left ventricular thrombus status Data are shown as n/N (%). 3 deaths before discharge. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; MRA, mineralocorticoid receptor antagonist; NSAID, non-steroidal anti-inflammatory drugs; P2Y12i, P2Y12 inhibitor; SGLT2i, SGLT2 inhibitor. Thrombus-positive patients had persistently lower model-estimated mean GLS values at follow-up (11.8%; 95% CI 9.8% to 13.8%) compared with thrombus-negative patients (15.5%; 95% CI 14% to 16.4%). Both groups significantly improved in LVEF over the 30-day follow-up period. In the thrombus-positive group, LVEF improved from 37.4% (95% CI 31.8% to 43%) at baseline to 45.3% (95% CI 39.5% to 51.1%) at day 30. However, systolic function remained impaired, with persistent akinesia affecting more than 20% of the myocardium. In contrast, the thrombus-negative group demonstrated normalisation of LVEF, increasing from 47.7% (95% CI 45.6% to 49.9%) to 55% (95% CI 52.6% to 57.4%), with complete resolution of akinesia (figure 2 and online supplemental table S1). Peak troponin levels were higher in the thrombus-positive group, and NT-proBNP levels remained persistently elevated in the thrombus-positive group throughout the study period (figure 3 and online supplemental table S2). Cox proportional hazards regression analysis identified reduced LVEF, impaired GLS and elevated peak troponin levels as predictors of LV thrombus formation (figure 4). Echocardiographic outcomes in patients with anterior STEMI with or without left ventricular thrombus. Echocardiographic outcomes include measurements of left ventricular ejection fraction (A), global longitudinal strain (B), tricuspid annular plane systolic excursion (C), wall motion score index (D) and proportion akinesia (E). Mixed effect models with points representing mean and point range representing 95% CIs (A–C) or tobit mixed model showing the median patient with lines representing 95% credible intervals (D–E).GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; TAPSE, tricuspid annular plane systolic excursion; WMSI, wall motion score index. Biomarkers in patients with anterior STEMI with or without left ventricular thrombus. Secondary laboratory outcomes include serum troponin-I (A), serum troponin-T (B), the troponin-I to troponin-T ratio (C), serum NT-proBNP (D), serum NT-proBNP/troponin-T ratio (E) and serum NT-proBNP/troponin-I ratio (F). Mixed effect models with points representing mean and point-range representing 95% CIs. cTnI, cardiac troponin-I; cTnT, cardiac troponin-T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; STEMI, ST-elevation myocardial infarction. Predictors of thrombus development in anterior STEMI via Cox proportional hazards regression analysis. Points represent HRs, and error bars represent 95% CIs. COPD, chronic obstructive pulmonary disease; cTnI, cardiac troponin-I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; TAPSE, tricuspid annular plane systolic excursion; STEMI, ST-elevation myocardial infarction. Clinical outcomes Among the 19 anterior STEMI patients with LV thrombus, one thromboembolic event (a TIA) was observed, representing an incidence of 5.3%. During the 30-day follow-up period, two patients (10.5%) in the thrombus-positive group were hospitalised for heart failure, and two (10.5%) experienced reinfarction, with one patient experiencing both events. No deaths were recorded within 30 days in the thrombus-positive group, whereas three non-cardiac deaths (2.3%) occurred in the thrombus-negative group during the same period (table 5). The patient who developed LV thrombus after non-anterior STEMI did not experience a thromboembolic event. Table 5Clinical outcomes in patients with anterior STEMI stratified by LV thrombus status.Clinical outcomesWith LV thrombus n=19Without LV thrombus n=1293-day outcomeMet criteria for cardiogenic shock* within 3 days2/19 (10.5%)18/129 (14.0%)Ventricular fibrillation within 3 days2/19 (10.5%)14/129 (10.9%)Sustained ventricular tachycardia within 3 days1/19 (5.3%)11/129 (8.5%)AV block grade III within 3 days0/19 (0.0%)2/129 (1.6%)AV block grade II within 3 days0/19 (0.0%)2/129 (1.6%)30-day outcomeDeath within 30 days0/19 (0.0%)3/129 (2.3%)Reinfarction within 30 days2/19 (10.5%)1/129 (0.8%)Hospitalisation for heart failure within 30 days2/19 (10.5%)1/129 (0.8%)Stroke or TIA within 30 days1/19 (5.3%)0/129 (0.0%)Thromboembolisation (excluding stroke or TIA) within 30 days0/19 (0.0%)0/129 (0.0%)6-month outcomeDeath within 6 months0/19 (0.0%)4/129 (3.3%)Reinfarction within 6 months2/19 (11.8%)2/129 (1.6%)Hospitalisation for heart failure within 6 months4/19 (23.5%)5/129 (4.1%)Stroke or TIA within 6 months1/19 (5.9%)0/129 (0.0%)Thromboembolisation (excluding stroke or TIA) within 6 months0/19 (0.0%)0/129 (0.0%)Data are shown as n/N (%)*, Defined as systolic blood pressure below 90 mmHg and signs of heart failure; AV, atrioventricular; LV, left ventricular; STEMI, ST-elevation myocardial infarction; TIA, transient ischeamic attack. Clinical outcomes in patients with anterior STEMI stratified by LV thrombus status. Data are shown as n/N (%) *, Defined as systolic blood pressure below 90 mmHg and signs of heart failure; AV, atrioventricular; LV, left ventricular; STEMI, ST-elevation myocardial infarction; TIA, transient ischeamic attack. Anticoagulation therapy All patients with LV thrombus were administered anticoagulation therapy in accordance with standard clinical guidelines. The initial treatment consisted of low-molecular weight heparin, transitioning to either warfarin or direct oral anticoagulants. The median duration of anticoagulation therapy was 3 months, with adjustments made based on follow-up imaging and clinical risk assessments. The thrombus negative patients were managed with standard postinfarction therapy, including antiplatelets, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and high-dose statins. No thromboembolic events, reinfarctions or heart failure-related hospitalisations were observed in the TS group during the 30-day follow-up period (online supplemental table S3). Discussion STAMI is the first prospective study to directly compare the incidence of LV thrombus in patients with TS and STEMI. Among 68 patients with TS and 246 with STEMI, LV thrombus was observed exclusively in STEMI patients, suggesting potential differences in the underlying pathophysiology. In STEMI, irreversible myocardial injury is likely to promote thrombus formation, whereas in TS, the transient nature of myocardial dysfunction may be associated with a lower propensity for thrombus formation. The incidence of LV thrombus in the STEMI group was 8.1%, with a significantly higher prevalence in anterior STEMI (12.8%) compared with non-anterior STEMI (1.0%). This is consistent with the previous findings, as anterior infarctions are more often associated with extensive myocardial injury and wall motion abnormalities, both of which promote thrombus formation.1216 A substantial proportion of thrombi were mural, and the high-resolution rate by day 30 may be explained by effective anticoagulation, combined with spontaneous or endogenous resolution, as components of Virchow’s triad improve over time.17 Nearly all LV thrombi were detected within the first week, with the majority identified on day 7 and only a few observed on days 0 and 1. In contrast, the median hospital stay after an acute myocardial infarction in Sweden is 3 days, with many patients undergoing echocardiography on day 0 or 1.18 Consequently, many LV thrombi may remain undetected, highlighting the need for improved surveillance after anterior STEMI. Importantly, several thrombi were first detected at the scheduled day 7 echocardiographic examination, which occurred after hospital discharge in many cases. Notably, our findings predominantly reflect thrombi that formed early after STEMI, a stage characterised by pronounced blood stasis, endothelial injury and a transient hypercoagulable state. Thrombi formed under these conditions are likely to be fresh and less organised, which may render them more susceptible to anticoagulant therapy as ventricular function improves and local flow is restored.19 20 This pathophysiological context, together with the study’s prospective design and systematic follow-up, may help explain the high thrombus resolution rates observed. Nearly all thrombi occurred in anterior STEMI, with older age and male sex being significant predictors of thrombus formation. Whether these associations are mediated by sex-related and age-related differences in infarct characteristics rather than reflecting direct effects of sex and age remains to be established. Despite extensive baseline LV dysfunction, no LV thrombi were identified in patients with TS. This is remarkable given that the majority of TS patients exhibited an apical ballooning phenotype with large areas of akinesia, conditions traditionally considered favourable for thrombus formation. While prior studies have reported thromboembolic events in TS, these are largely derived from retrospective or registry-based datasets with non-standardised imaging. In contrast, the present study incorporated predefined serial echocardiographic surveillance during the early phase, when thrombus formation is most likely to occur.2124 Both STEMI and TS patients showed significant improvement in cardiac function, as measured by LVEF and GLS, although recovery was less pronounced in STEMI patients with thrombus. This finding is consistent with a study by Meurin et al,24 which reported that among patients with STEMI, recovery of cardiac function was slower in those with thrombus. The rate of thrombus resolution with anticoagulation treatment was high, and only one thromboembolic complication was observed during follow-up. This study underscores the need to refine diagnostic strategies to identify high-risk TS and STEMI patients at risk of thrombus formation. Early detection using echocardiographic measures, such as LVEF and GLS, in combination with biomarker analysis, plays a crucial role in guiding clinical decisions. Enhancing screening protocols, particularly in patients with extensive anterior infarctions, could improve the early identification of thrombus formation and enable timely intervention. These findings provide valuable insights into thrombus incidence, predictors and resolution and support management strategies tailored to the specific characteristics of each condition. Larger prospective studies are warranted to confirm these findings and further clarify differences in thrombus formation between TS and STEMI. Limitations This study has several limitations. First, patients were enrolled at a limited number of hospitals in Western Sweden, which may restrict the generalisability of the findings. Although enrollment was prospective, inclusion occurred over a prolonged period and required informed consent and protocol-driven echocardiographic examinations, which may have introduced selection bias. Second, only STEMI patients presenting within 6 hours of symptom onset were included. As delayed presentation is associated with larger infarct size and a higher risk of LV thrombus formation, the true incidence of LV thrombus may therefore have been underestimated. Third, LV thrombus detection relied primarily on standard transthoracic echocardiography rather than routine contrast-enhanced echocardiography or cardiac MRI, which are more sensitive for thrombus detection. Nevertheless, standard echocardiography remains the first-line imaging modality in routine care and can identify clinically relevant LV thrombi reliably when the apex is adequately visualised. In our study, imaging was protocolised, serial and focused on endocardial border definition and apical assessment, with expert review of suspected thrombi and supplementary contrast echocardiography or cardiac MRI when uncertainty remained. Therefore, the use of more sensitive imaging would, if anything, be expected to increase the number of thrombi detected after STEMI, whereas the absence of thrombus in TS is unlikely to be explained solely by the imaging strategy. Conclusions Despite more extensive LV dysfunction in TS compared with STEMI, LV thrombus was observed exclusively in STEMI patients. Nearly all thrombi occurred in anterior STEMI and were detected within the first week, with a high-resolution rate by day 30. These findings underscore key pathophysiological differences between TS and STEMI, warranting further investigation and highlighting the need for condition-specific surveillance strategies. Supplementary material